JO3030B1 - مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات - Google Patents

مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات

Info

Publication number
JO3030B1
JO3030B1 JOP/2010/0179A JOP20100179A JO3030B1 JO 3030 B1 JO3030 B1 JO 3030B1 JO P20100179 A JOP20100179 A JO P20100179A JO 3030 B1 JO3030 B1 JO 3030B1
Authority
JO
Jordan
Prior art keywords
treatment
degenerative
inflammatory diseases
diseases
novel compound
Prior art date
Application number
JOP/2010/0179A
Other languages
English (en)
Inventor
Blanc Javier
Jeanne Marie Menet Christel
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of JO3030B1 publication Critical patent/JO3030B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

يتم الإفصاح عن أي مركب يحتوي على الصيغة التي يمثلها على النحو التالي: يمكن تحضير المركب الحالي كتوليفة صيدلانية ويمكن إستخدامه للوقاية والعلاج من الحالات المختلفة في الثدييات بما فيها البشر والمشتملة على أمثلة غير مقصورة على حالات الإلتهابات أو أمراض المناعة الذاتية أو أمراض التكاثري أو رفض الزراعة أو الأمراض المشتملة على تلف دوران الغضروف أو تشوهات الغضروف الخلقي و/أو الأمراض المصاحبة لفَرْطُ إِفْراز IL6.
JOP/2010/0179A 2009-06-26 2010-05-31 مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات JO3030B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25

Publications (1)

Publication Number Publication Date
JO3030B1 true JO3030B1 (ar) 2016-09-05

Family

ID=42340530

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0179A JO3030B1 (ar) 2009-06-26 2010-05-31 مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات

Country Status (37)

Country Link
US (2) US8796457B2 (ar)
EP (2) EP2792677B1 (ar)
JP (1) JP5486084B2 (ar)
KR (1) KR101712561B1 (ar)
CN (1) CN102459261B (ar)
AR (1) AR077221A1 (ar)
AU (1) AU2010264635B2 (ar)
BR (1) BRPI1014759A2 (ar)
CA (1) CA2765988C (ar)
CL (1) CL2011003276A1 (ar)
CO (1) CO6491039A2 (ar)
CR (1) CR20110673A (ar)
CY (1) CY1119711T1 (ar)
DK (2) DK2445912T3 (ar)
DO (1) DOP2011000378A (ar)
EA (1) EA020111B1 (ar)
ES (2) ES2519170T3 (ar)
HR (2) HRP20141057T1 (ar)
HU (1) HUE034205T2 (ar)
IL (1) IL216618A (ar)
JO (1) JO3030B1 (ar)
LT (1) LT2792677T (ar)
MA (1) MA33447B1 (ar)
ME (1) ME01916B (ar)
MX (1) MX2011013451A (ar)
NZ (1) NZ596836A (ar)
PE (1) PE20120494A1 (ar)
PL (2) PL2445912T3 (ar)
PT (2) PT2445912E (ar)
RS (1) RS53617B1 (ar)
SG (1) SG177359A1 (ar)
SI (2) SI2445912T1 (ar)
SM (2) SMT201700333T1 (ar)
TW (1) TWI469981B (ar)
UY (1) UY32741A (ar)
WO (1) WO2010149771A1 (ar)
ZA (1) ZA201109502B (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
SG10201914052TA (en) * 2011-10-11 2020-03-30 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
MY177334A (en) * 2012-06-22 2020-09-12 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
MA38884A1 (fr) 2013-09-05 2017-06-30 Hoffmann La Roche Composé de triazolopyridine, compositions et procédés d'utilisation associés
WO2015083028A1 (en) 2013-12-05 2015-06-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
SG11201708198SA (en) * 2015-04-13 2017-11-29 Galapagos Nv Methods for the treatment of cardiovascular disorders
US11414413B2 (en) 2016-07-26 2022-08-16 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof
US11427581B2 (en) 2018-01-31 2022-08-30 Zhuhai United Laboratories Co., Ltd. JAK inhibitor and use thereof
CN112955222A (zh) 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
TW202521583A (zh) 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
JP2022534794A (ja) 2019-06-04 2022-08-03 サノフィ・バイオテクノロジー 関節リウマチを有する対象における疼痛を治療するための組成物および方法
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US7122552B2 (en) * 2002-05-30 2006-10-17 Vertex Pharmaceuticals Incorporated Inhibitors of JAK and CDK2 protein kinases
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
CA2577478A1 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
SG174086A1 (en) * 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
CA2689514C (en) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
JP2010536917A (ja) 2007-08-31 2010-12-02 メルク セローノ ソシエテ アノニム トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
MX2011012961A (es) 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物

Also Published As

Publication number Publication date
HRP20171024T1 (hr) 2017-10-06
MX2011013451A (es) 2012-04-30
EP2792677A1 (en) 2014-10-22
PL2792677T3 (pl) 2017-09-29
CY1119711T1 (el) 2018-06-27
PT2792677T (pt) 2017-07-06
JP2012530767A (ja) 2012-12-06
SMT201400169B (it) 2015-01-15
WO2010149771A1 (en) 2010-12-29
CO6491039A2 (es) 2012-07-31
UY32741A (es) 2011-01-31
MA33447B1 (ar) 2012-07-03
TWI469981B (zh) 2015-01-21
SI2792677T1 (sl) 2017-08-31
TW201103937A (en) 2011-02-01
ES2519170T3 (es) 2014-11-06
IL216618A (en) 2014-09-30
DK2445912T3 (da) 2014-11-10
HK1168098A1 (en) 2012-12-21
HUE034205T2 (en) 2018-01-29
SG177359A1 (en) 2012-02-28
CA2765988A1 (en) 2010-12-29
KR20120059487A (ko) 2012-06-08
HRP20141057T1 (en) 2015-03-13
HK1202537A1 (en) 2015-10-02
CA2765988C (en) 2017-08-29
PL2445912T3 (pl) 2015-02-27
SMT201700333T1 (it) 2017-09-07
AU2010264635A1 (en) 2011-12-22
ME01916B (me) 2015-05-20
EP2792677B1 (en) 2017-04-26
US20100331359A1 (en) 2010-12-30
LT2792677T (lt) 2017-07-25
EP2445912B1 (en) 2014-08-13
ES2634325T3 (es) 2017-09-27
KR101712561B1 (ko) 2017-03-06
NZ596836A (en) 2013-02-22
SI2445912T1 (sl) 2014-12-31
CN102459261A (zh) 2012-05-16
US9505754B2 (en) 2016-11-29
EA201270076A1 (ru) 2012-08-30
RS53617B1 (sr) 2015-04-30
AU2010264635B2 (en) 2015-05-07
CL2011003276A1 (es) 2012-08-31
EA020111B1 (ru) 2014-08-29
DK2792677T3 (en) 2017-07-10
EP2445912A1 (en) 2012-05-02
US20150031671A1 (en) 2015-01-29
IL216618A0 (en) 2012-02-29
CN102459261B (zh) 2014-11-05
PT2445912E (pt) 2014-11-07
BRPI1014759A2 (pt) 2016-04-19
DOP2011000378A (es) 2012-02-15
JP5486084B2 (ja) 2014-05-07
US8796457B2 (en) 2014-08-05
ZA201109502B (en) 2012-09-26
CR20110673A (es) 2012-02-09
PE20120494A1 (es) 2012-05-17
AR077221A1 (es) 2011-08-10

Similar Documents

Publication Publication Date Title
JO3030B1 (ar) مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
MY156664A (en) 5-phenyl-[1, 2, 4]triazolo[1, 5-a]pyridin-2-yl carboxamides as jak inhibitors
PH12014502615B1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
GB201013307D0 (en) Anti-microbial metal organic framework
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
IN2012DN03883A (ar)
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
MX2012004780A (es) Inhibidores de akt.
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
UA105796C2 (uk) Сполука, застосовна для лікування дегенеративних і запальних захворювань
MX337145B (es) Composiciones farmaceuticas.
NZ803938A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
TN2011000020A1 (en) cMET INHIBITORS
CY1115695T1 (el) Νεα ενωση χρησιμη για τη θεραπεια εκφυλιστικων και φλεγμονωδων ασθενειων
PH12013501069A1 (en) Pharmaceutical compositions
UA103493C2 (en) cMET INHIBITORS
TN2010000583A1 (en) Organic compounds